L3VLUP
ProSign in

VKTX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VKTXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VKTX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterVKTXJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 20201 holders, $112k32 holders, $26.6bn
Q1 20211 holders, $245k31 holders, $25.3bn
Q2 20212 holders, $1.0m37 holders, $25.6bn
Q3 20212 holders, $769k40 holders, $24.1bn
Q4 20211 holders, $627k33 holders, $25.2bn
Q1 20221 holders, $290k35 holders, $28.2bn
Q2 20221 holders, $849k33 holders, $26.9bn
Q3 20222 holders, $3.5m36 holders, $25.4bn
Q4 20223 holders, $13m35 holders, $27.6bn
Q1 20234 holders, $71m42 holders, $24.5bn
Q2 20231 holders, $57m38 holders, $25.0bn
Q3 20233 holders, $54m37 holders, $18.9bn
Q4 20232 holders, $138m31 holders, $19.0bn
Q1 20247 holders, $1.6bn32 holders, $19.7bn
Q2 20245 holders, $961m35 holders, $20.4bn
Q3 20245 holders, $1.1bn28 holders, $22.3bn
Q4 20246 holders, $794m37 holders, $20.4bn
Q1 20254 holders, $61m32 holders, $20.5bn
Q2 20253 holders, $72m31 holders, $18.4bn
Q3 20256 holders, $117m32 holders, $23.7bn
Q4 20256 holders, $202m29 holders, $27.8bn
Q1 20262 holders, $156m34 holders, $35.6bn
Q2 20264 holders, $183m33 holders, $39.1bn
VKTX

Viking Therapeutics Inc

Holders
5
Reported value
$961m
Buyers
5
Sellers
1

Breadth +4 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
35
Reported value
$20.4bn
Buyers
24
Sellers
8

Breadth +16 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VKTX (2)

Discovery Capital Management LLC, Viking Global Investors LP

Only JNJ (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Squarepoint Ops LLC, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →